Skin rash is a common side effect of apalutamide, and even low-grade events can lead to dose reductions and discontinuation. Use this practical guidance for early identification and management to help your patients stay on treatment.
What are the latest advances in the ever-expanding list of treatment options for metastatic castration-resistant prostate cancer? And how can you best integrate these agents into your clinical practice?
A man receiving abiraterone for prostate cancer developed severe hypokalemia, which led to polymorphic ventricular tachycardia and cardiac arrest. It is important to consider iatrogenic causes in cases of arrhythmia.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)
In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.
Please note, this webinar is not intended for healthcare professionals based in the US and UK.
A man receiving abiraterone for prostate cancer developed severe hypokalemia, which led to polymorphic ventricular tachycardia and cardiac arrest. It is important to consider iatrogenic causes in cases of arrhythmia.
Adjuvant pembrolizumab treatment after resection of lung metastases in a patient with renal cell carcinoma may have led to lung erosion that resulted in a pneumothorax.
The first reported case of PERM associated with anti-glycine receptor antibodies in a patient with bladder cancer. PERM, a stiff-person syndrome, has paraneoplastic etiology in about 20% of cases.
Prostate cancer (PCa) relapse, defined either by persistent PSA levels (after RP) or biochemical recurrence (BCR), is a common occurrence. The imaging evaluation of patients experiencing PCa relapse has undergone significant advancements in the …
Hereditary renal mass syndromes, although rare, account for at least 3–5% of kidney cancers and significantly impact affected families. Accurate diagnosis and management by radiologists are crucial as these syndromes often present at imaging with …
Recognition of the importance of prostate-specific membrane antigen (PSMA) PET/CT in the diagnosis of prostate cancer has steadily increased following the publication of extensive data on its diagnostic accuracy and impact on patient management …
Many clinical trials have confirmed that programmed death-1 (PD-1) or Programmed cell death ligand 1 (PD-L1) inhibitors have excellent clinical efficacy for malignant tumors [ 1 – 87 ]. Due to their unique immune mechanism, many immune-related side …
An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.
Supported by:
Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Inguinal lymph node surgery is a standard treatment for penile cancer patients with intermediate or high risk for lymph node metastasis (LNM) according to European Association of Urology (EAU) risk grading. We are proposing a more objective …
Prostate cancer (PCa) is the second most common cancer among the United States men [ 1 ]. Although the incidence of PCa has remained stable over the past decade, the percentage of PCa cases diagnosed at a distant stage has increased from 3.9 to …
Recognition of the importance of prostate-specific membrane antigen (PSMA) PET/CT in the diagnosis of prostate cancer has steadily increased following the publication of extensive data on its diagnostic accuracy and impact on patient management …
Prostate cancer (PCa) is the second most common cancer in men, with an estimated 1.4 million diagnoses and 397,000 deaths worldwide in 2022. In Europe, it is the most commonly diagnosed cancer and the third leading cancer-related cause of death [ 1 …].
